Search clinical trials for: BSI-201 (Iniparib)

Total 5502 results

Sanofi

No longer available

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE)

Brain Metastases

France
Sanofi

Completed

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Advanced Epithelial Ovarian Cancer

United States
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Sanofi

Completed

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Tumors

United States
Sanofi
SOLTI Breast Cancer Research Group

Completed

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)

Breast Cancer Female

Spain, France, Germany
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

United States
Sanofi

Completed

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Advanced Solid Tumors

United States
Sanofi

Completed

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Tumors

United States
Sanofi
Gynecologic Oncology Group

Completed

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Uterine Carcinosarcoma

United States
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
Sanofi
BiPar Sciences

Completed

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Sanofi

Completed

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma

United States
Sanofi

Completed

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Advance Solid Tumors

Japan
Sanofi

Completed

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Neoplasm Malignant

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Sanofi

Completed

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer, Metastatic

Australia, Belgium, France, Italy, Netherlands, Spain
Chang Gung Memorial Hospital

Completed

Nonoperative Management Protocol in Patients With Blunt Splenic Injuries

Blunt Injuries
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
Sanofi
Breast Cancer Research Foundation

Completed

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Sanofi

Completed

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Spain, France, Germany, Italy, United Kingdom
Sanofi

Completed

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Breast Cancer

United States
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

COVID-19 | Sepsis | Acute Kidney Injury

United States
Sanofi

Completed

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Solid Tumors

Belgium, Italy, United States, Spain
Hookipa Biotech GmbH

Recruiting

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

HPV-Related Squamous Cell Carcinoma

United States, Spain, Netherlands
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-208

Androgenetic Alopecia

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Recruiting

Follow-up in Pediatric Intensive Care Unit (APRELAREA)

Intensive Care Psychosis

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Sanofi
UNC Lineberger Comprehensive Cancer Center

Completed

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Brain Metastases | Estrogen Receptor Negative (ER-Negative) Breast Cancer | Progesterone Receptor Negative (PR-Negative) Breast Cancer | Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer

United States
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Hypertension | Hyperlipidemias

Korea, Republic of
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
National Institutes of Health Clinical Center (CC)
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

Adrenal Insufficiency | Congenital Adrenal Hyperplasia (CAH) | Excess Androgen

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
BioSyngen Pte Ltd

Unknown

A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Malignant Ascites | Malignant Pleural Effusion

Australia
QurAlis Corporation

Recruiting

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Amyotrophic Lateral Sclerosis

Canada, Germany, Netherlands, Ireland, United Kingdom, Belgium
Emory University

Completed

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (FLU1)

Influenza

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Influenza

Germany
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization (SLVP023)

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
Sanofi

Completed

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (ECLIPSE)

Squamous Cell Lung Cancer

Canada, Belgium, Spain, United States, France, Germany, Hungary, Israel, Italy, Luxembourg, Netherlands, Poland, Romania, United Kingdom
Inter-American Development Bank

Completed

Randomized Trial of the Effects of Musical Training on Child Development in the Venezuela Orchestra Program (El Sistema)

Child Development
University of Southern Denmark
University of Copenhagen; University of Aarhus; The Danish Institute for Quality...

Unknown

The Effectiveness of a Nationwide Mandatory Accreditation in General Practice in Denmark (ACIAP)

Quality Control
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom

3

Subscribe